MedTrace Logo

Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT00963274 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-04-23

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of giving bortezomib and romidepsin together in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), indolent B-cell lymphoma, peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma (CTCL). Bortezomib and romidepsin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Conditions

Interventions

DRUG

Bortezomib

Starting dose: 1.3 mg/sq m

DRUG

Romidepsin

Starting dose: 8 mg/sq m

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Beata Holkova, MD · Massey Cancer Center

  • Thomas C. Shea, MD · UNC Lineberger Comprehensive Cancer Center

  • Steven Grant, MD · Virginia Commonwealth University

  • Sho Ma, MD, PhD · Northwestern University & Robert H Lurie Comprehensive Cancer Center

  • Amy Kimball, MD, PhD · University of Maryland Greenebaum Cancer Center

  • Nishitha Reddy, MBBS · Vanderbilt-Ingram Cancer Center, Vanderbilt University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-26
Primary Completion
2014-07-17
Completion
2018-04-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00963274 on ClinicalTrials.gov